

ASX Announcement

Share purchase plan – closing date extended

SYDNEY, Australia, 13 September 2023: Imugene Limited (ASX:IMU) (**Company**), refers to its ASX announcement on 18 August 2023 which announced a share purchase plan (**SPP**). The Record Date to be registered as an Eligible Shareholder for participation in the SPP was 17 August 2023.

The Company has received feedback that shareholders require further time to consider the SPP offer following two announcements released to market this week (*"Imugene Receives Positive Feedback From FDA"* and *"Imugene PD1-Vaxx Update"*). Accordingly, the Company has determined to extend the SPP Closing Date to Thursday, 21 September 2023 to allow shareholders more time to consider and respond to the SPP offer.

Updated SPP timetable

Event	Date
Record Date for SPP (7.00pm, Sydney time)	Thursday, 17 August 2023
Announcement of Placement and SPP	Friday, 18 August 2023
Opening Date of SPP	Monday, 28 August 2023
Closing Date for SPP	Thursday, 21 September 2023
Announce results of SPP and allotment of New Shares under the SPP	Tuesday, 26 September 2023
Normal ASX trading for New Shares issued under the SPP commences	Wednesday, 27 September 2023
Extraordinary general meeting to approve issuance of New Options and Directors' participation in the Placement	Thursday, 28 September 2023
Issuance of New Options and Placement Shares to Directors (subject to shareholder approval having been obtained)	Friday, 29 September 2023

The timetable is subject to change.

All other terms of the SPP as set out in the prospectus sent to Eligible Shareholders on 28 August 2023 remain unchanged.



Enquiries

A copy of the Prospectus is available via the Company's website at www.imugene.com or can be obtained by contacting the Company's Share Registry on the number noted below.

For further information relating to the Offer, please contact the Company's Share Registry, Automic Registry Service Limited, on 1300 288 664 (within Australia) or +61 2 9698 5414 (outside Australia), at any time between 8:30am and 5:30pm (AEST), Monday to Friday (excluding public holidays) until the closing date of the SPP and Options Offer.

For more information please contact:

Leslie Chong
Managing Director and Chief Executive Officer
info@imugene.com

Investor Enquiries
shareholderenquiries@imugene.com

Media Enquiries
Matt Wright
matt@nwrcommunications.com.au

Follow us on Twitter and Instagram @TeamImugene

Like us on Facebook @Imugene

Connect with us on LinkedIn @Imugene Limited

Watch us on YouTube @ImugeneLimited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel



(azercabtagene zapreleucel) which targets CD19 to attack blood cancer, multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Executive Chairman.

Not an offer in the United States

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements under the US Securities Act and applicable US state securities laws.